EXPEREO
Expereo, the world leading global intelligent internet company that connects people, places and things anywhere today announces the appointment of Ben Elms as Chief Executive Officer and Irwin Fouwels as Executive Chairman, effective May 1st, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410648166/en/
Ben Elms (Photo: Business Wire)
This strategic move is part of Expereo's commitment to driving sustained growth and building on its legacy of innovation and global customer success. With their combined experience in the telecommunications and technology sectors, Elms and Fouwels bring a wealth of expertise and leadership to their new roles within the business.
As CEO, Ben Elms will be responsible for driving the company's strategic vision, enhancing operational efficiency, and fostering innovation to meet the evolving needs of Expereo's global customer base. He brings over 25 years of relevant experience having held key executive roles at prominent firms and prior to joining Expereo as the CEO of Vodafone Global Enterprise Business, serving its multinational customers around the world.
Since joining in 2022 as Chief Revenue Officer, Elms has successfully led transformative initiatives such as expereoOne Expereo’s digital customer experience platform and driven its direct enterprise go-to-market strategy. This has positioned Expereo as a recognized global leader in delivering unique transformative customer value through its global enterprise network and cloud access solutions. In the first quarter of this year, Expereo launched its Enhanced Internet proposition, optimizing global cloud application performance through a proprietary AI-driven routing optimization platform. Leveraging Elms’ strong background in IoT and mobility, Expereo also added enterprise grade Fixed Wireless Access and Low Orbit Satellite solutions to its wide array of managed global connectivity solutions.
Elms commented; "I am honoured to lead Expereo during this exciting next phase of growth and innovation. Expereo has established itself as a global leader in internet-based connectivity solutions, and I look forward to working closely with the talented team to drive further success and deliver unparalleled value to our direct enterprise and wholesale customers. We have a strong foundation and a reputation for excellence in the industry. I am thrilled to lead the company with Irwin’s support as Executive Chairman. With the entire team we will capitalize on new opportunities, further expand our market presence, and drive continued innovation including driven by increased adoption of AI and the opportunities that creates for Expereo – “faster to the future”."
Fouwels, assuming the role of Executive Chairman brings a strategic mindset and a passion for innovation which has contributed to Expereo’s success. As Expereo CEO over the last decade, he has transformed and scaled Expereo to the world leading global intelligent internet company delivering unparalleled internet performance, led the company through multiple investor rounds and a series of acquisitions whilst delivering strong financial performance and investor returns.
Fouwels commented; “It is a privilege working with the global Expereo team and its investment partners over the last decade delivering unique value to our customers in a dynamic technology and telecoms market. We have been pivotal in transforming the way global enterprises architect global connectivity and application performance, leveraging the agility of the internet, whilst making it enterprise grade in terms of performance and security. And this anywhere on the globe, through any access technology.
Over the last two years Ben as CRO has been invaluable in accelerating our growth path, strengthening our go to market in direct enterprise whilst ensuring scalability throughout the organization, driving further automation, transformation and building global recognition of the Expereo brand and notably transforming expereoOne to a unique digital customer experience and platform. expereoOne turns the fragmented global internet landscape into a unique one-touch customer experience and has grown significantly with the addition of a large number of globally recognised large multinational enterprise customers. Ben has also brought in exceptional talent, strengthening the team as a foundation for further growth and solid financial performance. I am very much looking forward to working alongside Ben providing strategic guidance and supporting Expereo's leadership team”.
With Elms’ and Fouwels’ combined leadership, industry knowledge and track record of success they are confident in accelerating Expereo’s growth trajectory, and in delivering exceptional value to their customers and partners.
About Expereo
Expereo is the world leading intelligent internet company that connects people, places, and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to any location worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility, and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners which acquired a majority shareholding from Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410648166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom